Simulations Plus, Inc. Declares Quarterly Dividend, Payable on February 1, 2019
January 09, 2019 at 04:05 pm
Share
The Board of Directors of Simulations Plus, Inc. declared quarterly a cash dividend of $0.06 per share of the company’s common stock, payable on February 1, 2019, to shareholders of record as of January 25, 2019.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
SIMULATIONS PLUS, INC. 
